

ASX ANNOUNCEMENT

27 January 2016

TB and Gonorrhoea

Recce Ltd is pleased to announce that laboratory tests have shown RECCE® antibiotic is able to kill the following pathogenic bacteria:

- a) *Mycobacterium fortuitum*¹ (model for TB disease); and
- b) *Neisseria gonorrhoeae*² (causing gonorrhoea)

Importantly, RECCE® antibiotics, as part of a *technology* are targeted at a variety of applications, against a variety of diseases. The *technology* (in contrast to a lone product) gives the investor security should unexpectedly negative results cause a particular application to lose favour. This would mean total failure within Recce's technology would be improbable, in view of the range of alternatives available.

Particularly –

- a) The observed effectiveness against *Mycobacterium fortuitum* is important since this bacterium is a model for *Mycobacterium tuberculosis* – the cause of tuberculosis disease, specified by World Health Organisation (WHO) as one of the world's most threatening diseases. In 2012, 8.7 million people developed TB and 1.3 million died as a result of the disease.
- b) The observed effectiveness against *Neisseria gonorrhoeae* is important since gonorrhoea is increasing alarmingly; WHO estimates there were 106 million new cases of gonorrhoea globally. The bacterium has increasing resistance against existing antibiotics; treatment of the venereal disease often demands the use of valuable, last-resort cephalosporin antibiotics.

Dr Graham Melrose, Executive Chairman of Recce Ltd, commented "In this urgent field - it is rewarding and encouraging to again see RECCE® antibiotics producing results".

¹ Total kill in 24 hours (2000ppm of antibiotic)

² Total kill in 20 minutes (1000ppm of antibiotic)

For further information please visit www.recce.com.au or contact:

Investor Relations

Peter Williams
CFO & Company Secretary
Recce Ltd
Tel: +61 8 9253 9800

Media Communication

Karen Oswald – karen.oswald@markocommunications.com.au
Gary Buchholz – gary@markocommunications.com.au
Marko Communications
Tel: +61 423 602 353

About Recce Ltd

Recce Ltd (ASX: RCE), led by Dr Graham Melrose, is a world-leader in synthetic-polymer antibiotics. RECCE® antibiotics have been synthesised by an extremely simple and economic method.

RECCE® antibiotics have shown in laboratory tests that they have continued activity against bacteria including superbugs, even after repeated use.

Recce is positioned to achieve milestones in both pre-clinical trials for FDA purposes and the development of a pilot plant for flow-system manufacture of RECCE® antibiotics - that should drive significant value for the Company.

